{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine&page=26", "query": { "intervention": "Endocrine", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 877, "total_pages": 88, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endocrine&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T14:44:21.343Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04729985", "title": "Diabetes Discharge Transitional CGM Study (DDT-CGM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "CGM device with diabetic education, CGM education and a follow up protocol.", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Intermountain Health Care, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2021-06-01", "completion_date": "2024-12-01", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 1, "location_summary": "Logan, Utah", "locations": [ { "city": "Logan", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729985" }, { "nct_id": "NCT05759949", "title": "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA Mutation", "Solid Tumor, Adult", "HER2-negative Breast Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Unresectable Solid Tumor", "Hormone Receptor Positive Tumor" ], "interventions": [ { "name": "RLY-5836", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-03-29", "completion_date": "2025-04-11", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 7, "location_summary": "Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05759949" }, { "nct_id": "NCT00044291", "title": "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasms, Hormone-dependent" ], "interventions": [ { "name": "atamestane", "type": "DRUG" }, { "name": "toremifene", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "aromatase inhibition", "type": "DRUG" }, { "name": "hormone therapy", "type": "PROCEDURE" }, { "name": "endocrine therapy", "type": "PROCEDURE" }, { "name": "antiestrogen therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Intarcia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 865, "start_date": "2002-06", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2015-07-31", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 17, "location_summary": "Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more", "locations": [ { "city": "Lake Havasu City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami Shores", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044291" }, { "nct_id": "NCT05465408", "title": "Culturally Aware AET Non-Initiation Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Survivorship", "Treatment Compliance", "Treatment Adherence", "Treatment Refusal" ], "interventions": [ { "name": "Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2022-07-21", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 11, "location_summary": "Boston, Massachusetts • Brighton, Massachusetts • Concord, Massachusetts + 7 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Brighton", "state": "Massachusetts" }, { "city": "Concord", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05465408" }, { "nct_id": "NCT07483307", "title": "A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-negative Breast Cancer", "HER2 Negative Breast Carcinoma", "ER+ Breast Cancer", "Lobular Breast Carcinoma" ], "interventions": [ { "name": "Neoadjuvant endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 176, "start_date": "2026-03-13", "completion_date": "2030-03-13", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07483307" }, { "nct_id": "NCT04958109", "title": "Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metabolic Diseases" ], "interventions": [ { "name": "Oral Glucose Tolerance Test", "type": "DIAGNOSTIC_TEST" }, { "name": "Kisspeptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 16, "start_date": "2021-10-28", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04958109" }, { "nct_id": "NCT04430660", "title": "Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes", "Hypoglycemia" ], "interventions": [ { "name": "13C-MRS procedure/Acetate infusion", "type": "OTHER" }, { "name": "Continuous glucose monitoring", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Pennington Biomedical Research Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 8, "start_date": "2020-08-19", "completion_date": "2022-05-04", "has_results": false, "last_update_posted_date": "2023-03-09", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 2, "location_summary": "Baton Rouge, Louisiana • New Orleans, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430660" }, { "nct_id": "NCT00569582", "title": "A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cushing's Syndrome" ], "interventions": [ { "name": "mifepristone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2007-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-08-22", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Escondido, California • Stanford, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Escondido", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569582" }, { "nct_id": "NCT00066690", "title": "Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor Positive Breast Cancer", "Progesterone Receptor Positive Tumor", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "Exemestane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oophorectomy", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Triptorelin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "ETOP IBCSG Partners Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 3066, "start_date": "2003-12-17", "completion_date": "2024-11-06", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 480, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066690" }, { "nct_id": "NCT05516797", "title": "IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Continuous Glucose Monitoring (CGM)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "HealthPartners Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2022-09-22", "completion_date": "2024-03-01", "has_results": true, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-11-06T14:44:21.343Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05516797" } ] }